SI-BONE Valuation
Is SIBN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of SIBN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate SIBN's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate SIBN's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SIBN?
Key metric: As SIBN is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is SIBN's PS Ratio? | |
|---|---|
| PS Ratio | 3.5x |
| Sales | US$157.04m |
| Market Cap | US$541.84m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.7x |
| Enterprise Value/EBITDA | -11.4x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does SIBN's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2.7x | ||
AXGN Axogen | 3.1x | 11.0% | US$556.3m |
TMCI Treace Medical Concepts | 2.3x | 8.2% | US$474.1m |
SRDX Surmodics | 4.4x | 11.7% | US$552.4m |
OFIX Orthofix Medical | 0.9x | 6.2% | US$690.9m |
SIBN SI-BONE | 3.5x | 16.6% | US$541.8m |
Price-To-Sales vs Peers: SIBN is expensive based on its Price-To-Sales Ratio (3.5x) compared to the peer average (2.7x).
Price to Sales Ratio vs Industry
How does SIBN's PS Ratio compare vs other companies in the US Medical Equipment Industry?
Price-To-Sales vs Industry: SIBN is expensive based on its Price-To-Sales Ratio (3.5x) compared to the US Medical Equipment industry average (3.2x).
Price to Sales Ratio vs Fair Ratio
What is SIBN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 3.5x |
| Fair PS Ratio | 4.1x |
Price-To-Sales vs Fair Ratio: SIBN is good value based on its Price-To-Sales Ratio (3.5x) compared to the estimated Fair Price-To-Sales Ratio (4.1x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$12.92 | US$23.22 +79.7% | 18.0% | US$32.00 | US$18.00 | n/a | 9 |
| Nov ’25 | US$13.49 | US$23.33 +73.0% | 20.3% | US$32.00 | US$16.00 | n/a | 9 |
| Oct ’25 | US$13.62 | US$23.56 +72.9% | 18.8% | US$32.00 | US$18.00 | n/a | 9 |
| Sep ’25 | US$16.62 | US$23.56 +41.7% | 18.8% | US$32.00 | US$18.00 | n/a | 9 |
| Aug ’25 | US$14.84 | US$25.11 +69.2% | 15.4% | US$32.00 | US$20.00 | n/a | 9 |
| Jul ’25 | US$12.90 | US$25.56 +98.1% | 14.1% | US$32.00 | US$20.00 | n/a | 9 |
| Jun ’25 | US$14.05 | US$25.56 +81.9% | 14.1% | US$32.00 | US$20.00 | n/a | 9 |
| May ’25 | US$14.51 | US$26.22 +80.7% | 12.2% | US$32.00 | US$20.00 | n/a | 9 |
| Apr ’25 | US$15.78 | US$26.67 +69.0% | 9.4% | US$32.00 | US$24.00 | n/a | 9 |
| Mar ’25 | US$17.08 | US$26.88 +57.3% | 9.6% | US$32.00 | US$24.00 | n/a | 8 |
| Feb ’25 | US$20.64 | US$27.00 +30.8% | 9.1% | US$32.00 | US$25.00 | n/a | 8 |
| Jan ’25 | US$20.99 | US$26.38 +25.7% | 10.5% | US$32.00 | US$24.00 | n/a | 8 |
| Dec ’24 | US$18.82 | US$25.63 +36.2% | 13.1% | US$32.00 | US$22.00 | n/a | 8 |
| Nov ’24 | US$17.26 | US$28.38 +64.4% | 12.2% | US$32.00 | US$22.00 | US$13.49 | 8 |
| Oct ’24 | US$21.24 | US$30.63 +44.2% | 5.6% | US$33.00 | US$27.00 | US$13.62 | 8 |
| Sep ’24 | US$22.61 | US$30.63 +35.4% | 5.6% | US$33.00 | US$27.00 | US$16.62 | 8 |
| Aug ’24 | US$25.68 | US$30.75 +19.7% | 6.5% | US$33.00 | US$27.00 | US$14.84 | 8 |
| Jul ’24 | US$26.98 | US$29.50 +9.3% | 7.0% | US$33.00 | US$27.00 | US$12.90 | 8 |
| Jun ’24 | US$25.23 | US$28.88 +14.4% | 5.6% | US$32.00 | US$27.00 | US$14.05 | 8 |
| May ’24 | US$22.60 | US$24.29 +7.5% | 14.2% | US$32.00 | US$20.00 | US$14.51 | 7 |
| Apr ’24 | US$19.67 | US$24.29 +23.5% | 14.2% | US$32.00 | US$20.00 | US$15.78 | 7 |
| Mar ’24 | US$20.01 | US$24.50 +22.4% | 13.4% | US$32.00 | US$20.00 | US$17.08 | 8 |
| Feb ’24 | US$17.05 | US$21.63 +26.8% | 19.7% | US$32.00 | US$17.00 | US$20.64 | 8 |
| Jan ’24 | US$13.60 | US$22.13 +62.7% | 18.8% | US$32.00 | US$17.00 | US$20.99 | 8 |
| Dec ’23 | US$12.68 | US$22.75 +79.4% | 16.6% | US$32.00 | US$20.00 | US$18.82 | 8 |
| Nov ’23 | US$18.68 | US$24.13 +29.1% | 20.7% | US$36.00 | US$20.00 | US$17.26 | 8 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Centene
US$29.0b
Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.
CNC
US$57.46
7D
-4.5%
1Y
-20.9%
Lantheus Holdings
US$5.3b
Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.
LNTH
US$76.83
7D
-12.2%
1Y
12.7%
electroCore
US$70.5m
A commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally.
ECOR
US$10.94
7D
-18.9%
1Y
78.2%